Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,553.71
(
-0.74%
)
US TECH 100
29,705.20
(
-0.47%
)
Dow Jones
50,687.07
(
-1.21%
)
Brent Oil
97.06
(
1.89%
)
Bitcoin
65,352.69
(
-2.00%
)
News Focus
News Focus

Replies to post #305549 on Innovation Pharmaceuticals Inc (IPIX)

Replies to #305549 on Innovation Pharmaceuticals Inc (IPIX)
icon url

PlentyParanoid

06/24/20 6:49 PM

#305564 RE: MinnieM #305549

"News of a surprise nature that none of us even think to anticipate"

Let's be a whimsical and try to anticipate. I mentioned this before. Aprea is due to complete (primary) a phase III study of P53 re-activator (APR-246) in treatment of Mutant Myelodysplastic Syndromes (MDS) by the end of this year. IPIX's Kevetrin might get some "MeToo" action if APR-246 trial is successful. Currently my cloudy crystal ball is showing exactly that. Dunno what it will show after cleaning.
icon url

attilathehunt

06/24/20 7:11 PM

#305572 RE: MinnieM #305549

I added too!

Almost 10% worth at .0397
icon url

Yooper61

06/24/20 8:51 PM

#305600 RE: MinnieM #305549

Leo stated at the sh meeting that there were claw back provisions if AS did not perform. That is my hope. If I were an AS exec right now, I’d be busting my ass to get a trial going, given the last few PR’s. I hope we claw it back. A deal made in desperation. Then we would have the entire digestive track to sell.